Abstract
Ovarian cancer is an “intraperitoneal disease” by itself. When first standard treatment fails, usually, the disease is characterized by poor prognosis. Encouraging results have been reported by the treatment of peritoneal carcinomatosis (PC) from epithelial ovarian cancer (EOC) by complete surgical cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). The purpose of this study is to evaluate survival benefit and morbidity of patients with recurrent EOC treated by cytoreductive surgery and HIPEC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
